Ruben Abagyan

ORCID

Publication Activity (10 Years)

Years Active: 2018-2024
Publications (10 Years): 32

Top Venues

JMIRx med

PloS one

medRxiv : the preprint server for health sciences

PLoS computational biology

University of California San Diego

This page only lists publications with an associated author ORCID identifier.

Affiliation History

University of California San Diego Sep 01 2009

United States

Professor :: Skaggs School of Pharmacy and Pharmaceutical Sciences

Publications

Tigran Makunts, Siranuysh Grabska, Hovakim Grabski, Ruben Abagyan
Co-occurring infections in cancer patients treated with checkpoint inhibitors significantly increase the risk of immune related adverse events. medRxiv : the preprint server for health sciences (2024)
Eugene Raush, Ruben Abagyan, Maxim Totrov
Efficient Generation of Conformer Ensembles Using Internal Coordinates and a Generative Directional Graph Convolution Neural Network. Journal of chemical theory and computation (2024)
Tigran Makunts, Siranuysh Grabska, Hovakim Grabski, Ruben Abagyan
Co-occurring infections in cancer patients treated with checkpoint inhibitors significantly increase the risk of immune related adverse events. medRxiv : the preprint server for health sciences (2024)
Tigran Makunts, Haroutyun Joulfayan, Ruben Abagyan
Authors' Response to Peer Reviews of "Thyroid Hyperplasia and Neoplasm Adverse Events Associated With Glucagon-Like Peptide-1 Receptor Agonists in the Food and Drug Administration Adverse Event Reporting System: Retrospective Analysis". JMIRx med 5 (2024)
Tigran Makunts, Haroutyun Joulfayan, Ruben Abagyan
Thyroid Hyperplasia and Neoplasm Adverse Events Associated With Glucagon-Like Peptide-1 Receptor Agonists in the Food and Drug Administration Adverse Event Reporting System: Retrospective Analysis. JMIRx med 5 (2024)
Tigran Makunts, Haroutyun Joulfayan, Ruben Abagyan
Thyroid Hyperplasia and Neoplasm Adverse Events Associated With Glucagon-Like Peptide-1 Receptor Agonists in the Food and Drug Administration Adverse Event Reporting System: Retrospective Analysis. JMIRx med 5 (2024)
Tigran Makunts, Siranuysh Grabska, Hovakim Grabski, Ruben Abagyan
Co-occurring infections in cancer patients treated with checkpoint inhibitors significantly increase the risk of immune related adverse events. medRxiv : the preprint server for health sciences (2024)
Tigran Makunts, Siranuysh Grabska, Hovakim Grabski, Ruben Abagyan
Co-occurring infections in cancer patients treated with checkpoint inhibitors significantly increase the risk of immune related adverse events. medRxiv : the preprint server for health sciences (2024)
Eugene Raush, Ruben Abagyan, Maxim Totrov
Efficient Generation of Conformer Ensembles Using Internal Coordinates and a Generative Directional Graph Convolution Neural Network. Journal of chemical theory and computation 20 (9) (2024)
Tigran Makunts, Haroutyun Joulfayan, Ruben Abagyan
Authors' Response to Peer Reviews of "Thyroid Hyperplasia and Neoplasm Adverse Events Associated With Glucagon-Like Peptide-1 Receptor Agonists in the Food and Drug Administration Adverse Event Reporting System: Retrospective Analysis". JMIRx med 5 (2024)
Tigran Makunts, Haroutyun Joulfayan, Ruben Abagyan
Thyroid Hyperplasia and Neoplasm Adverse Events Associated With Glucagon-Like Peptide-1 Receptor Agonists in the Food and Drug Administration Adverse Event Reporting System: Retrospective Analysis. JMIRx med 5 (2024)
Tigran Makunts, Haroutyun Joulfayan, Ruben Abagyan
Thyroid Hyperplasia and Neoplasm Adverse Events Associated With Glucagon-Like Peptide-1 Receptor Agonists in the Food and Drug Administration Adverse Event Reporting System: Retrospective Analysis. JMIRx med 5 (2024)
Tigran Makunts, Haroutyun Joulfayan, Ruben Abagyan
Authors' Response to Peer Reviews of "Thyroid Hyperplasia and Neoplasm Adverse Events Associated With Glucagon-Like Peptide-1 Receptor Agonists in the Food and Drug Administration Adverse Event Reporting System: Retrospective Analysis". JMIRx med 5 (2024)
Conall Sauvey, Ittipat Meewan, Gretchen Ehrenkaufer, Jonathan Blevitt, Paul Jackson, Ruben Abagyan
High-throughput phenotypic screen identifies a new family of potent anti-amoebic compounds. PloS one 18 (5) (2023)
Conall Sauvey, Ittipat Meewan, Gretchen Ehrenkaufer, Jonathan Blevitt, Paul Jackson, Ruben Abagyan
High-throughput phenotypic screen identifies a new family of potent anti-amoebic compounds. PloS one 18 (5) (2023)
Tigran Makunts, Haroutyun Joulfayan, Ruben Abagyan
Thyroid hyperplasia and neoplasm adverse events associated with GLP-1 receptor agonists in FDA Adverse Event Reporting System. medRxiv : the preprint server for health sciences (2023)
Tigran Makunts, Keith Burkhart, Ruben Abagyan, Peter Lee
Retrospective analysis of clinical trial safety data for pembrolizumab reveals the effect of co-occurring infections on immune-related adverse events. PloS one 17 (2) (2022)
Thomas G Bartholow, Terra Sztain, Megan A Young, D John Lee, Tony D Davis, Ruben Abagyan, Michael D Burkart
Control of Unsaturation in De Novo Fatty Acid Biosynthesis by FabA. Biochemistry 61 (7) (2022)
Sara Brin Rosenthal, Hao Wang, Da Shi, Cin Liu, Ruben Abagyan, Linda K McEvoy, Chi-Hua Chen
Mapping the gene network landscape of Alzheimer's disease through integrating genomics and transcriptomics. PLoS computational biology 18 (2) (2022)
Eugene Raush, Ruben Abagyan, Maxim Totrov
Graph-Convolutional Neural Net Model of the Statistical Torsion Profiles for Small Organic Molecules. Journal of chemical information and modeling (2022)
Vi N Nguyen, Ruben Abagyan, Shirley M Tsunoda
Mtor inhibitors associated with higher cardiovascular adverse events-A large population database analysis. Clinical transplantation 35 (4) (2021)
Zhaoping Xiong, Minji Jeon, Robert J Allaway, Jaewoo Kang, Donghyeon Park, Jinhyuk Lee, Hwisang Jeon, Miyoung Ko, Hualiang Jiang, Mingyue Zheng, Aik Choon Tan, Xindi Guo, null null, Kristen K Dang, Alex Tropsha, Chana Hecht, Tirtha K Das, Heather A Carlson, Ruben Abagyan, Justin Guinney, Avner Schlessinger, Ross Cagan
Crowdsourced identification of multi-target kinase inhibitors for RET- and TAU- based disease: The Multi-Targeting Drug DREAM Challenge. PLoS computational biology 17 (9) (2021)
Conall Sauvey, Gretchen Ehrenkaufer, Da Shi, Anjan Debnath, Ruben Abagyan
Antineoplastic kinase inhibitors: A new class of potent anti-amoebic compounds. PLoS neglected tropical diseases 15 (2) (2021)
George Nicola, Irina Kufareva, Andrey V Ilatovskiy, Ruben Abagyan
Druggable exosites of the human kino-pocketome. Journal of computer-aided molecular design 34 (3) (2020)
Hye Jee Hahn, Ruben Abagyan, Larissa M Podust, Shantanu Roy, Ibne Karim M Ali, Anjan Debnath
HMG-CoA Reductase Inhibitors as Drug Leads against Naegleria fowleri. ACS chemical neuroscience 11 (19) (2020)
Jing Gu, Yongjia Huang, Zijun Yan, Dan He, Yonghong Zhang, Jingyu Xu, Yao Li, Xuemei Xie, Jiaxi Xie, Da Shi, Ruben Abagyan, Jingqing Zhang, Qunyou Tan
Biomimetic Membrane-Structured Nanovesicles Carrying a Supramolecular Enzyme to Cure Lung Cancer. ACS applied materials & interfaces 12 (28) (2020)
Da Shi, Feroz Khan, Ruben Abagyan
Extended Multitarget Pharmacology of Anticancer Drugs. Journal of chemical information and modeling 59 (6) (2019)
Da Shi, Kirti Kandhwal Chahal, Patricia Oto, Louis-Felix Nothias, Anjan Debnath, James H McKerrow, Larissa M Podust, Ruben Abagyan
Identification of Four Amoebicidal Nontoxic Compounds by a Molecular Docking Screen of Naegleria fowleri Sterol Δ8-Δ7-Isomerase and Phenotypic Assays. ACS infectious diseases 5 (12) (2019)
Benoît Bestgen, Isabelle Krimm, Irina Kufareva, Ahmed Ashraf Moustafa Kamal, Wei-Guang Seetoh, Chris Abell, Rolf Wolfgang Hartmann, Ruben Abagyan, Claude Cochet, Marc Le Borgne, Matthias Engel, Thierry Lomberget
2-Aminothiazole Derivatives as Selective Allosteric Modulators of the Protein Kinase CK2. 1. Identification of an Allosteric Binding Site. Journal of medicinal chemistry 62 (4) (2019)
Benoît Bestgen, Irina Kufareva, Wei-Guang Seetoh, Chris Abell, Rolf Wolfgang Hartmann, Ruben Abagyan, Marc Le Borgne, Odile Filhol-Cochet, Claude Cochet, Thierry Lomberget, Matthias Engel
2-Aminothiazole Derivatives as Selective Allosteric Modulators of the Protein Kinase CK2. 2. Structure-Based Optimization and Investigation of Effects Specific to the Allosteric Mode of Action. Journal of medicinal chemistry 62 (4) (2019)
Kirti Kandhwal Chahal, Jie Li, Irina Kufareva, Milind Parle, Donald L Durden, Robert J Wechsler-Reya, Clark C Chen, Ruben Abagyan
Nilotinib, an approved leukemia drug, inhibits smoothened signaling in Hedgehog-dependent medulloblastoma. PloS one 14 (9) (2019)
Tigran Makunts, Isaac V Cohen, Kelly C Lee, Ruben Abagyan
Population scale retrospective analysis reveals distinctive antidepressant and anxiolytic effects of diclofenac, ketoprofen and naproxen in patients with pain. PloS one 13 (4) (2018)

Ruben Abagyan.css-eqlu8i{font-size:small;padding-left:4px;}

Publication Activity (10 Years)

Top Topics

Top Venues

Ruben Abagyan